Class I - Dangerous
Marketed without an Approved NDA/ANDA: Product contains undeclared sildenafil which was discovered through FDA analysis.
💊
Prescription Drugs
💊 Drugs • 12,141 recalls
CGMP Deviation; Possible contamination with impurity N-nitrosodimethylamine.
Class I - Dangerous
Defective Delivery System: Out of specification for mechanical peel and shear.
Maximum Strength Acid Reducer, Cool Mint Ranitidine tablets, USP 150 mg, 95 tablets per bottle. [Brand, NDC] NDC Basic Care: 0113-7950-01; NDC CVS Health: 59779-950-01
Perrigo Company PLC
Class I - Dangerous
CGMP Deviation; Possible contamination with impurity N-nitrosodimethylamine.
CGMP Deviation; Possible contamination with impurity N-nitrosodimethylamine.
Sodium Chloride 0.9% Injection, USP, 1000 mL bags, Rx only, Manufactured by: Fresenius Medical Care North America, Waltham, MA 02451
Fresenius Medical Care Holdings
Class I - Dangerous
CGMP Deviation: Chemical indicators were not positioned properly during sterilization process.
Doxycycline Capsules, USP, 75 mg, 100-count bottle, Rx only, Manufactured by: Ohm Laboratories Inc., New Brunswick, NJ 08901; Distributed by Sun Pharmaceutical Industries, Inc., Cranbury, NJ 08512; NDC 63304-615-01.
Sun Pharmaceutical Industries
Class I - Dangerous
CGMP Deviations: Doxycycline capsules were not manufactured under Current Good Manufacturing Practice conditions.
Regular Strength Acid Reducer, Ranitidine tablets, USP 75 mg, 160 tablets per bottle. [NDC: Brand] NDC CVS Health.: 69842-293-06
Perrigo Company PLC
Class I - Dangerous
CGMP Deviation; Possible contamination with impurity N-nitrosodimethylamine.
Class I - Dangerous
Presence of Foreign Tablets/Capsules: This is a spin-off recall of D-1581-2019 due to a product complaint where one of Lupin's Fenofibrate 145mg was observed in the 500 s count product bottle.
Maximum Strength Acid Reducer, Ranitidine tablets, USP 150 mg, 90 tablets per bottle. [Brand, NDC] NDC Equate: 49035-608-75; NDC Up & Up: 11673-023-75
Perrigo Company PLC
Class I - Dangerous
CGMP Deviation; Possible contamination with impurity N-nitrosodimethylamine.
Maximum Strength Acid Reducer, Cool Mint Ranitidine tablets, USP 150 mg, 40 tablets per bottle. [Brand, NDC] NDC Up & Up: 11673-950-58
Perrigo Company PLC
Class I - Dangerous
CGMP Deviation; Possible contamination with impurity N-nitrosodimethylamine.
Class I - Dangerous
CGMP Deviation; Possible contamination with impurity N-nitrosodimethylamine.
CGMP Deviation; Possible contamination with impurity N-nitrosodimethylamine.
Potassium Chloride Extended-Release Tablets USP, 10mEq (750mg), 1000-count bottle, Rx only, Manufactured by: Strides Shasun Limited Bengaluru - 562106, India, Distributed by: Strides Pharma Inc., East Brunswick, NJ 08816, NDC 64380-861-08
Strides Pharma Science Limited
Class I - Dangerous
Failed Tablet/Capsules Specifications: Oversized tablets were found in one lot of Potassium Chloride Tablets 750 mg.
Class I - Dangerous
Defective Delivery System: Out of specification for mechanical peel and shear.
Class I - Dangerous
Defective Delivery System: Out of specification for mechanical peel and shear.
Doxycycline Capsules, USP, 100 mg, 50-count bottle, Rx only, Manufactured by: Ohm Laboratories Inc., New Brunswick, NJ 08901; Distributed by Sun Pharmaceutical Industries, Inc., Cranbury, NJ 08512; NDC 63304-616-50.
Sun Pharmaceutical Industries
Class I - Dangerous
CGMP Deviations: Doxycycline capsules were not manufactured under Current Good Manufacturing Practice conditions.
CGMP Deviation; Possible contamination with impurity N-nitrosodimethylamine.
Class I - Dangerous
CGMP Deviation; Possible contamination with impurity N-nitrosodimethylamine.
Regular Strength Acid Reducer, Ranitidine tablets, USP 75 mg, 150 tablets per bottle. [NDC: Brand] NDC H.E.B.: 37808-876-47; NDC Equate: 49035-876-47
Perrigo Company PLC
Class I - Dangerous
CGMP Deviation; Possible contamination with impurity N-nitrosodimethylamine.